Capricor shares surge 94% on FDA rethink of Duchenne drug
Capricor Therapeutics shares jumped as much as 94% intraday after the US Food and Drug Administration signalled willingness to review additional data for deramiocel, the company's experimental therapy for Duchenne muscular dystrophy.…
Ashin Xavier: interesting
IO Repro: Repro test v4 after fix 2 Oct. Safe to trash.
IO Repro: Repro test v3 after fix 2 Oct. Safe to trash.
IO Repro: Repro test after fix 2 Oct. Safe to trash.